Two-Drug Combination Shows Promise for Type 1 Diabetes Remission in Early Research

Type 1 diabetes develops when the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. Existing therapies like anti-CD3 can slow this attack, but reversing the disease likely requires a two-part strategy: calming the immune attack *and* helping beta cells recover.

Researchers tested whether combining harmine (a compound that promotes beta-cell growth) with exendin-4 (a hormone that improves beta-cell function) could achieve both goals at once.

In laboratory studies, harmine plus exendin-4 reduced beta-cell death caused by inflammation and suppressed immune pathways that damage beta cells. The combination also improved how well the beta cells functioned.

When researchers tested the combination in mice with recent-onset Type 1 diabetes, harmine plus exendin-4 alone did not reverse disease. But when combined with a low dose of anti-CD3 therapy, the results were striking: blood glucose normalized, insulin levels rose, glucose tolerance improved, and the amount of functional beta-cell tissue increased.

The combination also changed immune activity in beneficial ways—reducing harmful inflammatory T cells while increasing regulatory T cells that help control inflammation. Importantly, the treatment did not wipe out the entire immune system.

Genetic analysis revealed that a molecule called SNHG6 appears to be central to how harmine plus exendin-4 protects beta cells. In stress conditions, SNHG6 shielded beta cells from damage, prevented cell death, and reduced signals that make beta cells targets for immune attack.

This discovery could eventually lead to new strategies that directly boost SNHG6 or its function, offering another avenue for protecting beta cells during inflammation.

These findings offer a proof-of-concept that combining immune modulation with beta-cell regeneration and protection may enable remission of recent-onset Type 1 diabetes. The results suggest a path forward for future combination therapies.

This work is still in early stages—conducted in mice and human cell samples in the laboratory. Clinical trials in people would be required to determine whether this approach is safe and effective in real-world Type 1 diabetes.

Source: bioRxiv : the preprint server for biology. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.